Bohle Uni Cone BUC®
With the innovative and patented Bohle Uni Cone BUC® process a complete fluidization is assured which leads to a high coating uniformities and high yields in the final product.
L.B. Bohle developed the Bohle Fluid Bed Systems with tangentially mounted spray nozzles and the Bohle Uni Cone BUC®. This equipment is available for batch sizes ranging from 1 to 500 kg.
With the innovative and patented Bohle Uni Cone BUC® process a complete fluidization is assured which leads to a high coating uniformities and high yields in the final product due to the absence if particle twinning. Bohle Uni Cone BUC ® is the productive, practical and precise alternative to conventional Wurster processing.
By design all size fluid beds are geometrically similar which enables an easy scale up procedure. Dust free suction and discharge of the product bowl is performed through the use of a newly developed patented multi-functional valve directly above the distributer plate. The overall design of the BFS types results in substantial ergonomic benefits, which means major advantages in cleanability and processing in comparison to other existing fluid bed systems on the market. In addition, the low position of the valve allows easy operator access. Bohle Fluid Bed Systems contain fewer gaskets, valves and vents, which makes cleaning fast and easy.
All Bohle systems utilize a very efficient use of space.
Contact Details:
Tobias Borgers
Phone
: +49 (0) 2524 9323 150
Fax
: +49 (0) 2524 9323 399
Website:www.lbbohle.com
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
